This blog gives you the latest topical news plus some informal comments on them from ShareSoc’s directors and other contributors. These are the personal comments of the authors and not necessarily the considered views of ShareSoc. The writers may hold shares in the companies mentioned. You can add your own comments on the blog posts, but note that ShareSoc reserves the right to remove or edit comments where they are inappropriate or defamatory.

AZN AstraZeneca – Company Information and Vote Guidance

You must be logged in as ShareSoc or SIGnet member to access this page. Login here to view this page, or sign up if you are not yet a member, to obtain an account for our website.

2 Comments
  1. Mark Bentley says:

    Whilst the CEO’s remuneration may be high, as a fellow shareholder I find it hard to begrudge him his award. IMO he has done a phenomenal job since he was appointed to the role. When he took over, Astra was a company in trouble, facing a “patent expiry cliff edge”. He took the bold decision to cancel the company’s share buyback programme and invest the free cashflow in research instead, with a promise to return the company to a growth path. That promise is now being delivered with multiple new “blockbuster” drugs now in the market, generating growth in revenues and profits (and better treatments for patients), and several more potential blockbusters in the pipeline.

  2. Cliff Weight says:

    Big article in Mail on Sunday https://www.thisismoney.co.uk/money/markets/article-9556845/Furious-AstraZeneca-pay-clash-rocks-City-Clash-bonus-hike.html
    Furious AstraZeneca pay clash rocks City: Top investors at loggerheads over £2.3m bonus hike for boss Pascal Soriot who delivered jabs triumph
    Soriot is at the centre of an extraordinary row among City investors over his multi-million-pound bonus
    The plan could take his overall pay, which includes his £1.3million salary and other perks, well above the £15.4million he received last year
    Two top shareholders – Aviva Investors and Standard Life Aberdeen – have already voted to block the proposals ahead of the company’s annual meeting.

    The French chief executive has been lauded for rolling out Astra’s life-saving Covid vaccine at no profit, as well as fighting off predatory buyers and boosting the company’s share price since he took charge in 2012.

    But Astra’s major shareholders are understood to have been locked in heated talks for days after the drugs giant proposed to boost his bonus and performance-related share award by £2.3million to £12million. The award could be worth even more if the share price rises.

    The plan could take his overall pay, which includes his £1.3million salary and other perks, well above the £15.4million he received last year.

    The Mail on Sunday can reveal that two top shareholders – Aviva Investors and Standard Life Aberdeen – have already voted to block the proposals ahead of the company’s annual meeting on Tuesday. One said the pay hike threatened to ‘tarnish’ the £101 billion pharmaceutical firm’s reputation after its triumph in delivering an affordable Covid vaccine for the world.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

join sharesoc

Get more stuff

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.

Other Blog Posts
Other News